SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 196 filers reported holding SANGAMO THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 1.93 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2021 | $1,802,000 | -46.1% | 200,000 | -28.3% | 0.06% | -46.1% |
Q2 2021 | $3,341,000 | -17.3% | 279,100 | -13.5% | 0.12% | -23.3% |
Q1 2021 | $4,042,000 | -34.0% | 322,600 | -17.8% | 0.15% | -46.2% |
Q4 2020 | $6,122,000 | +75.1% | 392,300 | +6.0% | 0.28% | +54.1% |
Q3 2020 | $3,497,000 | -3.6% | 370,100 | -8.6% | 0.18% | -10.8% |
Q2 2020 | $3,629,000 | +26.3% | 405,000 | -10.2% | 0.20% | -1.0% |
Q1 2020 | $2,873,000 | +75.9% | 451,000 | +131.2% | 0.20% | +122.8% |
Q4 2019 | $1,633,000 | -27.8% | 195,100 | -22.0% | 0.09% | -32.8% |
Q3 2019 | $2,263,000 | +19.7% | 250,100 | +42.4% | 0.14% | +18.1% |
Q2 2019 | $1,891,000 | +27.0% | 175,600 | +12.5% | 0.12% | +26.1% |
Q1 2019 | $1,489,000 | +292.9% | 156,100 | +373.0% | 0.09% | +253.8% |
Q4 2018 | $379,000 | -85.5% | 33,000 | -78.6% | 0.03% | -83.0% |
Q3 2018 | $2,619,000 | +137.9% | 154,500 | +99.4% | 0.15% | +131.8% |
Q2 2018 | $1,101,000 | +189.7% | 77,500 | +287.5% | 0.07% | +175.0% |
Q1 2018 | $380,000 | – | 20,000 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Golden State Equity Partners | 154,360 | $897,000 | 0.45% |
Rhenman & Partners Asset Management AB | 761,429 | $4,424,000 | 0.44% |
Lombard Odier Asset Management (Switzerland) SA | 860,702 | $5,001,000 | 0.39% |
WASATCH ADVISORS LP | 10,576,997 | $61,452,000 | 0.30% |
Rokos Capital Management LLP | 977,663 | $5,861,000 | 0.27% |
KLK CAPITAL MANAGEMENT LLC | 44,323 | $258,000 | 0.26% |
Long Focus Capital Management, LLC | 340,000 | $1,975,000 | 0.25% |
Vanguard Capital Wealth Advisors | 33,380 | $193,000 | 0.14% |
Fort Sheridan Advisors LLC | 73,978 | $430,000 | 0.13% |
Delphia (USA) Inc. | 20,983 | $122,000 | 0.09% |